PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer

Journal of Neuro-Oncology

Volumn 117, Issue 1, 2014, Pages 7-13

  Peddi, Parvin F ^a   Hurvitz, Sara A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain metastases; Breast cancer; Human epidermal growth factor receptor 2 (HER2); Mammalian target of rapamycin (mTOR); Phosphatidylinositol 3 kinase (PI3K)

Indexed keywords

BUPARLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROTEIN KINASE B; TRASTUZUMAB;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; DIARRHEA; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TARGETING; DRUG TUMOR LEVEL; ENZYME ACTIVATION; ENZYME INHIBITION; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; MOOD DISORDER; NAUSEA; NONHUMAN; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84901602898     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1369-6     Document Type: Review

References (62)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
2. Geyer CE, Forster J, Lindquist D, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743
3. Baselga J, Cortes J, Kim SB, et al. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119
4. Verma S, Miles D, Gianni L, et al. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791
5. Brufsky AM, Mayer M, Rugo HS, et al. (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17:4834-4843
6. Souglakos J, Vamvakas L, Apostolaki S, et al. (2006) Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res 8:R36
7. Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278-5286
8. Berghoff A, Bago-Horvath Z, De Vries C, et al. (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106:440-446
9. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648-1655
10. Bendell JC, Domchek SM, Burstein HJ, et al. (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977
11. Palmieri D, Bronder JL, Herring JM, et al. (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67:4190-4198
12. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18:23-28
13. Laufman LR, Forsthoefel KF (2001) Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2:235
14. Oliveira M, Braga S, Passos-Coelho JL, Fonseca R, Oliveira J (2011) Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 127:841-844
15. Platini C, Long J, Walter S (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7:778-780
16. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978-1980
17. Taskar KS, Rudraraju V, Mittapalli RK, et al. (2012) Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 29:770-781
18. Gril B, Palmieri D, Bronder JL, et al. (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092-1103
19. Cameron D, Casey M, Press M, et al. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543
20. Lin NU, Dieras V, Paul D, et al. (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452-1459
21. Bachelot T, Romieu G, Campone M, et al. (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64-71
22. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644
23. Baselga J (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16(suppl 1):12-19
24. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
25. Gewinner C, Wang ZC, Richardson A, et al. (2009) Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16:115-125
26. Dibble CC, Asara JM, Manning BD (2009) Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 29:5657-5670
27. O'Reilly KE, Rojo F, She QB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res 66:1500-1508
28. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. (2010) PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126:1121-1131
29. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70
30. Berns K, Horlings HM, Hennessy BT, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402
31. Jegg AM, Ward TM, Iorns E, et al. (2012) PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Res Treat 136:683-692
32. Adamo B, Deal AM, Burrows E, et al. (2011) Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res 13:R125
33. Hohensee I, Lamszus K, Riethdorf S, et al. (2013) Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. Am J Pathol 183:83-95
34. O'Reilly T, McSheehy PM, Kawai R, et al. (2010) Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 65:625-639
35. Franz DN, Belousova E, Sparagana S, et al. (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125-132
36. Baselga J, Campone M, Piccart M, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529
37. Andre F, Campone M, O'Regan R, et al. (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28:5110-5115
38. Morrow PK, Wulf GM, Ensor J, et al. (2011) Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29:3126-3132
39. O'Regan R, Ozguroglu M, Andre F, et al. (2013) Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 31 (suppl; abstr 505)
40. Zhao H, Cui K, Nie F, et al. (2012) The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res Treat 131:425-436
41. Wolff AC, Lazar AA, Bondarenko I, et al. (2013) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31:195-202
42. Galanis E, Buckner JC, Maurer MJ, et al. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304
43. Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O (2013) Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer 133(5):1222-1233
44. Carracedo A, Ma L, Teruya-Feldstein J, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3 K-dependent feedback loop in human cancer. J Clin Invest 118:3065-3074
45. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al. (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1:248-259
46. Maira SM, Pecchi S, Huang A, et al. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-Kinase inhibitor. Mol Cancer Ther 11:317-328
47. Nanni P, Nicoletti G, Palladini A, et al. (2012) Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(-/-);Il2rg(-/-) Mice and Treatment with PI3K Inhibitor. PLoS One 7:e39626
48. Maira M, Schnell C, Lollini P, et al. (2012) Preclinical and preliminary clinical activity of NVP-BKM120, an oral pan-class I PI3K inhibitor, in the brain. Ann Oncol 23 (suppl 9; abstr 1675)
49. Wen P, Yung W, Mellinghoff I, et al. (2013) Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). J Clin Oncol 31 (suppl; abstr 2015)
50. Bendell JC, Rodon J, Burris HA, et al. (2012) Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30:282-290
51. Pistilli B, Urruticoechea A, Chan S, et al. (2012) Ph Ib/II study of BKM120 plus trastuzumab (T) in patients with T-resistant HER2+ advanced breast cancer (BC). Ann Oncol 23 (suppl 9; abstr 3180)
52. Tohda C, Nakanishi R, Kadowaki M (2009) Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase. Brain Dev 31:69-74
53. Ackermann TF, Hortnagl H, Wolfer DP, et al. (2008) Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem 22:735-744
54. Koul D, Shen R, Kim YW, et al. (2010) Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12:559-569
55. Hong DS, Bowles DW, Falchook GS, et al. (2012) A multicenter Phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18:4173-4182
56. Edelman G, Bedell C, Shapiro G (2010) A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 28(6):1075-1083 (suppl; abstr 3004)
57. Cloughesy TF, Mischel P, Omuro A, et al. (2013) Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. J Clin Oncol 31 (suppl; abstr 2012)
58. Liu TJ, Koul D, LaFortune T, et al. (2009) NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8:2204-2210
59. Krop I, Saura C, Rodon J, et al. (2012) A Phase I/Ib dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. J Clin Oncol 30(12):282-290 suppl; abstr 508
60. Brana I, LoRusso P, Baselga J, et al. (2010) A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 28 (suppl; abstr 3030)
61. Salphati L, Heffron TP, Alicke B, et al. (2012) Targeting the PI3K pathway in the brain-efficacy of a pi3k inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res 18:6239-6248
62. Peddi PF, Hurvitz SA (2014) What Does the Future Hold for PI3K/AKT/mTOR Inhibitors in BreastCancer? J OncoPathol 1(4):73-81